The global market for Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment is experiencing significant growth, driven by a rising need for effective solutions against these infections. According to a new report by Future Market Insights (FMI), the market size reached US$ 3.9 billion in 2022 and is projected to climb to US$ 5.5 billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 4.3%.
This growth highlights the increasing global demand for innovative treatments to combat MRSA infections. Future Market Insights, a leading provider of market research and consultancy services, is well-positioned to capitalize on this lucrative opportunity. With its unwavering commitment to cutting-edge research and development, FMI remains at the forefront of the fight against MRSA, offering groundbreaking solutions to address the evolving challenges associated with this drug-resistant pathogen.
Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-10406
Challenges Marring Market Growth:
However, the MRSA treatment market also faces limitations. Limited access to effective treatments and misdiagnoses of MRSA infections are the primary factors impeding market expansion. Additionally, the high costs associated with MRSA treatment, particularly in emerging economies, are expected to restrain adoption rates.
Furthermore, inaccurate diagnoses can lead to inappropriate treatment plans, potentially resulting in severe complications and even death. These factors pose a significant challenge to market growth in the near future.
Future Market Insights’ Role in the Fight Against MRSA:
Future Market Insights recognizes the critical need to address these challenges to ensure effective MRSA treatment reaches those who need it most. Through its commitment to in-depth research and industry insights, FMI empowers healthcare providers and policymakers with the knowledge needed to make informed decisions regarding MRSA treatment strategies and resource allocation.
By working collaboratively with stakeholders across the healthcare landscape, Future Market Insights is dedicated to fostering advancements in MRSA treatment and diagnostics, ultimately contributing to a healthier future for all.
Key Takeaways of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry Study:
- In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.
- By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
- By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
- Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
- North America is the highest revenue generating market by region due to high incidence of MRSA infections
- Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2021, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.
Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-10406
Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treat:
As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.
Key Companies Profiled:
- Pfizer, Inc.
- Allergan Plc.
- Johnsons & Johnson
- Colgate-Palmolive Company
- The Procter & Gamble
- Merck & Co., Inc.
- Baxter Healthcare Corporation
- Fresenius Kabi LLC
- Sandoz Inc.
- Teva Pharmaceutical Industries ltd.
- Mylan N. V.
- Dr.Reddy’s Laboratories Inc.,
- Cumberland Pharmaceuticals Inc.
Act Now to Explore In-Depth Market Analysis: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/10406
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry By Category:
By Drug Class:
- Glycopeptides
- Vancomycin
- Oxazolidinones
- Linezolid
- Lipopeptides
- Daptomycin
- Antiseptics
- Chlorhexidine
- Cetylpyridinium Chloride
- Hydrogen Peroxide
- Phenols
- Lipoglycopeptides
- Dalbavancin
- Telavancin
- Oritavancin
- Glycylcycline
- Tigecycline
- Streptogramins
- Quinupristin
- Dalfopristin
- Naturals/Herbals
- Tetracycline
- Doxycycline
- Minocycline
- Lincomycin
- Clindamycin
- Others
By Indication:
- Skin and Soft Tissue Infections (SSTIs)
- Pneumonia
- Bloodstream Infections
- Surgical and Medical Infections
- Others
By Route of Administration:
- Intravenous
- Oral
- Topical
- Nasal
- Cutaneous
- Intramuscular
By Type of MSRA:
- Healthcare Acquired MRSA
- Community Acquired MRSA
- Hospital Acquired MRSA
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
